Mycosyst (Fluconazole)

Fluconazole inhibits the fungal cytochrome P450 enzyme 14α‑demethylase, a key step in converting lanosterol to ergosterol, an essential component of the fungal cell membrane. By blocking ergosterol synthesis, the drug disrupts membrane integrity, inhibiting fungal growth and leading to cell death.

The dosage of Mycosyst is individualized by the prescribing clinician based on the specific infection, severity, patient weight, renal function, and other clinical factors. Healthcare providers determine the appropriate amount, frequency, and duration of therapy in accordance with current medical guidelines.

Safety of fluconazole in pregnancy and lactation depends on the dose and indication. Low‑dose, short‑term therapy may be considered when benefits outweigh risks, but higher or prolonged doses are generally avoided. Breastfeeding mothers should consult their physician, as fluconazole is excreted in milk.

To place an order, submit an enquiry on the Mycosyst product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Fluconazole, the active component of Mycosyst, offers oral administration, good bioavailability, and a broad spectrum against Candida species and Cryptococcus. Compared with amphotericin B, it is less toxic and can be given outpatient, though it may be less effective against resistant strains where echinocandins or newer azoles might be preferred.

Mycosyst should be stored at ambient temperature, below 25 °C, in its original packaging to protect it from moisture and light. Keep the product out of reach of children and avoid storing it in areas with high humidity or temperature fluctuations.

Mycosyst is taken orally, usually with or without food, as directed by the prescribing clinician. The tablet (or capsule) should be swallowed whole with a glass of water. Patients should follow the exact dosing schedule and complete the full course of therapy, even if symptoms improve.

Serious adverse reactions to fluconazole include hepatotoxicity, severe skin reactions such as Stevens‑Johnson syndrome or toxic epidermal necrolysis, anaphylaxis, and cardiac arrhythmias related to QT prolongation. Patients should seek immediate medical attention if they experience jaundice, rash, fever, or irregular heartbeat.

Mycosyst is contraindicated in individuals with known hypersensitivity to fluconazole or other azole antifungals. Caution is also advised for patients with severe liver disease, significant renal impairment, or those taking medications that have major interactions with fluconazole. The prescribing clinician should evaluate suitability before initiating therapy.